6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial

Joo‐Yong Hahn(Samsung Medical Center), Seung‐Hyuk Choi(Seoul National University of Science and Technology), Byung Ok Kim, Hyeon‐Cheol Gwon(Samsung Medical Center), Joon‐Hyung Doh(Inje University Ilsan Paik Hospital), In‐Ho Chae(Seoul National University Hospital), Jang Hyun Cho, Jeong Hoon Yang(Samsung Medical Center), Woong Choi(Konkuk University Medical Center), Wang Soo Lee(Chung-Ang University Hospital), Jong‐Seon Park(Korea University Medical Center), Seung‐Ho Hur(Keimyung University Dongsan Medical Center), Deok‐Kyu Cho(Severance Hospital), Young Bin Song(Samsung Medical Center), Jihoon Kim(University of California San Diego), Jin‐Yong Hwang(Chonnam National University), Il‐Woo Suh(University of Ulsan), Seung‐Woon Rha, Taek Kyu Park(Samsung Medical Center), Jin‐Ok Jeong(Chungnam National University Hospital), Ju Hyeon Oh(Chonnam National University Hospital), Rak Kyung Choi(Samsung Medical Center), Won You Kang, Hun Sik Park(Kyungpook National University Hospital), Sang‐Hyun Kim(Seoul National University), Jong‐Young Lee(Samsung Medical Center), Jang‐Ho Bae(Konyang University Hospital), Hoon-Ki Park(Veterans Health Service Medical Center), Jin Bae Lee(Daegu Catholic University Medical Center), Seong‐Hoon Lim, Doo‐Il Kim(Inje University Haeundae Paik Hospital), Sang Cheol Cho(Chonnam National University Hospital), Ki Hong Choi(Samsung Medical Center), Kwang Soo

The Lancet

March 1, 2018

Cited by 372

Related Papers

|ACS Nano|2015|706

|New England Journal of Medicine|2011|683

|JAMA|2015|603

|JAMA|2020|548

|New England Journal of Medicine|2010|510